Pharmacoeconomics of pharmaceutical interventions related to dosage form in a hospital complex in southern Brazil

Authors

DOI:

https://doi.org/10.30968/rbfhss.2023.142.0953

Abstract

Objective: To identify and quantify the pharmaceutical interventions (PI) related to adequate dosage form and measure the actual and potential avoidable expenses. Methods: Cross-sectional study of quantitative approach with retrospective data collection for the year 2021, conducted in a hospital complex in Porto Alegre with 1089 hospital beds. The study included the PI of adequacy of dosage form to the prescribed dose and evaluated the drugs involved, the acceptability by the medical team and the financial impact. Data were exported from NoHarm.ai®️ and compiled into a Microsoft Office Excel®️ structured spreadsheet. The study was approved by the Ethics Committee of the institution under opinion no. 37227020.6.0000.5335. Results: During the study period, 634,547 prescriptions were written, of which 142,177 (22.41%) were evaluated by clinical pharmacists. From this evaluation, 4,918 PI were made, of which 432 (8.78%) referred to dosage form. After applying the selection criteria, 79 (18.29%) PI were excluded, resulting in 353 (81.71%). The analyzed FI were grouped into three outcomes: accepted 191 (54.11%), not accepted 151 (42.78%), and 11 (3.11%) not applicable. Among the 191 accepted interventions, 135 (70.68%) resulted in changing the dosage form of the prescribed drug, generating savings of US$6,553.97 per year for the institution and 56 (29.32%) resulted in reevaluation of the treatment leading to suspension of the drug. For the 151 unaccepted interventions, a potential savings of US$3,575,13 per year was estimated if the intervention was accepted. The drugs with the highest number of interventions were: enoxaparin (24.93%), ondansetron (21.37%) and methadone (11.24%). From another angle, the drugs that presented the greatest financial impact from the accepted interventions were: epoetin alfa (51.76%), morphine (19.08%) and enoxaparin (10.49%). Conclusion: Clinical pharmacist ajust drug dosage during prescription review over a one-year period accounted for approximately 9% of interventions and generated cost savings of $6,500, demonstrating the clinical and economic importance of prescription evaluation by the clinical pharmacist.

Downloads

Download data is not yet available.

References

Lago AD, Ferreira TT, Carvalho AF, et al. Evaluation of Pharmaceutical Interventions: study carried out in a Pediatric ICU of the University Hospital Materno Infantil in São Luís - MA. Research, Society and Development. 2022;11(7):1-8. DOI: 10.33448/rsd-v11i7.29839

Rosa AW, Silva SR, Jesus RA, et al. Classification of pharmaceutical interventions carried. Brazilian Journal of Development. 2020;6(6):40165-76. DOI: 10.34117/bjdv6n6-524

Silva NR, Leopardi-Gonçalves MG, Oliveira AV, et al. Relevance of pharmaceutical in hospital clinical practice. Research, Society and Development. 2022;11(7):1-7. DOI: 10.33448/rsd-v11i7.29992.

Reinau D, Furrer C, Stämpfli D, et al. Evaluation of drug-related problems and subsequent clinical pharmacists’ interventions at a Swiss university hospital. J Clin Pharm Ther. 2019;44(6):924-31. DOI: 10.1111/jcpt.13017.

Spezia IA, Cimarosti HI. Identification of drugs-related problems and pharmacists’ interventions in a hospital in Southern Brazil. Rev Bras Farm Hosp Serv Saude. 2022;13(2):0794. DOI: 10.30968/rbfhss.2022.132.0794.

Brito AM, Negretto GW, Martinbiancho JK, et al. Analysis of pharmaceutical interventions using a pharmaceutical monitoring instrument in a Pediatric Intensive Care Unit. Clin Biomed Res. 2022;42(2):112-20. DOI: 10.22491/2357-9730.119401

Colin SL, Nutti C. Pharmaceutical intervention: Description of the role of the clinical pharmacist in intensive care units. Rev Bras Farm Hosp Serv Saude. 2022;13(2):0766. DOI: 10.30968/rbfhss.2022.132.0766.

Arantes T, Durval CC, Pinto VB. Evaluation of cost savings generated through pharmaceutical interventions performed in a large tertiary university hospital. Clin Biomed Res. 2021;40(2):96-104. DOI: 10.22491/2357-9730.95646

Oliveira LC, Andrade LM, Cardoso GC, et al. Analysis of pharmaceutical interventions on avoidable costs with pharmacotherapy in a teaching hospital in Sergipe (Brazil) in the first months of Covid-19. Rev Bras Farm Hosp Serv Saude. 2021;12(4):0705. DOI: 10.30968/rbfhss.2021.124.0705.

Gallagher J, McCarthy S, Byrne S. Economic evaluations of clinical pharmacist interventions on hospital inpatients: a systematic review of recent literature. Int J Clin Pharm. 2014;36(6):1101-14. DOI: 10.1007/s11096-014-0008-9

Mi X, Su X, Jin Z, et al. Economic evaluations of clinical pharmacy services in China: a systematic review. Bmj Open. 2020;10(1):1-13. DOI: 10.1136/bmjopen-2019-034862.

Silvia RF, Leite FP, Severino KS, et al. Pharmacoeconomics: the impact of its applicability in a hospital foundation. Revista Eletrônica Acervo Saúde. 2021;13(6):1-9. DOI: 10.25248/reas.e7804.2021.

Banco Central do Brasil. Currency converter [conversor de moedas]. Disponível em: https://www.bcb.gov.br/conversao. Acesso em 12 de dezembro de 2023.

Lindiara Luiza de Oliveria Campos. Minimização de custo por meio de intervenções farmacêuticas em hospital do Espírito Santo no período de 12 meses [Dissertação]. Universidade de Vila Velha, Vila Velha, 2021.

Published

2023-06-29

How to Cite

1.
ORTMANN BD, HOFFMANN TD, BLATT CR. Pharmacoeconomics of pharmaceutical interventions related to dosage form in a hospital complex in southern Brazil. Rev Bras Farm Hosp Serv Saude [Internet]. 2023Jun.29 [cited 2024Jul.20];14(2):953. Available from: https://rbfhss.org.br/sbrafh/article/view/953

Issue

Section

ORIGINAL ARTICLES

Most read articles by the same author(s)